News
Gilead Sciences (NASDAQ: GILD) didn't have a bad first quarter, but investors didn't find it inspiring either. After ...
The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha ...
Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...
The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...
Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...
A Cardington man was indicted Thursday on 41 counts in a case involving pandering sexually oriented materials involving ...
Pharmaceutical stocks are making headlines today, after two U.S.-based sector heavyweights stepped into the earnings ...
Reports Q1 reveue $6.7B, consensus $6.81B. “Gilead (GILD) had a strong start to the year driven by excellent commercial and clinical execution ...
"The Handmaid's Tale" may be coming to an end, but the world of Gilead is not with a sequel, "The Testaments," in production ...
WARNING: The following story contains spoilers about the fifth episode of The Handmaid's Tale's sixth and final season, ...
(Nasdaq: GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback